A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
A phase 3 trial of Selpercatinib in non-small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT04819100 by Eli Lilly and Company, with 152 participants enrolled, started 2021-12-20 and due to reach its primary completion in 2026-01-12. Interventions recorded: Selpercatinib and Placebo.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Shares Eli Lilly (incl. Loxo), Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Shares Eli Lilly (incl. Loxo), Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.